Onconova Therapeutics®, Inc., founded in 1998, is a privately held biopharmaceutical company, which discovers and develops novel small molecule therapeutics targeting signal transduction, cell-cycle regulation, and DNA repair.

Our drug candidates include kinase inhibitors directed at validated and novel targets, these drug candidates are derived internally from a proprietary library of new chemical entities.

The Company has developed this innovative discovery platform focusing on non-ATP competitive chemotypes.

Onconova has a broad range of capabilities, from medicinal chemistry and drug discovery to drug development and clinical trials.

For additional information please visit www.onconova.com.